|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 09, 2012 ) New York, NY -- Five stocks to follow at mid week, as reported by VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors.
Human Genome Sciences (HGSI): Long on potential but short on results has been the name of the game for the lupus-treating drug Benlysta since its commercial launch last year, but an offer last month by Human Genome's partner GlaxoSmithKline (GSK) to purchase the company has not only reinvigorated investor interest in the company's pipeline, but it also sparked a quick rally in the HGSI share price that returned investors about a double overnight.
The swift rally placed HGSI right in line with the valuation of Glaxo's offer, which stood at $2.6 billion and a $13 share price.
As was the case with other high profile takeover offers this year, specifically in regards to Illumina Inc. (ILMN) rejecting two offers from Roche Holding AG (RHHBY) and Amylin Pharmaceuticals (ALMN) saying thanks but no thanks to Bristol-Myers Squibb Company (BMY), Human Genome quickly rejected the Glaxo offer and called into question the valuation of the deal.
TrovaGene, Inc. (TROV): TrovaGene Inc. has been a stock to watch lately as volume and news catalysts picked up enough over the past couple of weeks to support a near double in share price. The company has announced some key additions to its management team in an effort to boost its leverage in bringing a unique diagnostics technology to market.
TrovaGene is developing different diagnostic tests that, if successful in development, would be able to detect numerous cancer types and various infectious diseases by identifying specific transrenal DNA and RNA originating from normal and diseased cell death in urine.
The market for such diagnostics is over $20 billion and with a strong position of patents and technology, TROV has the potential to chip away at a significant portion of that market share. Although early along in development, early studies have demonstrated that TrovaGene's technology could be superior and more accurate to the current market standards, and the company also boasts a strong patent position to protect is proprietary assets moving forward.
In addition to adding Dr. Carlo Croce, already a key player in the field of trans-renal molecular diagnostics, to the scientific team, the latest share price rally was supported by news that the company had made progress regarding the development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens.
Until April TrovaGene had been trading relatively under the radar, in terms of volume, but the recent news bytes have put this one back on the map.
This week's action shows that investors are now paying attention.
Premier Alliance Group (PIMO): The trading range for shares of Premier Alliance Group (PIMO) has become more active as volume has started to flow in over the past couple of months, and a quick look at the increasing volume since early 2012 shows that investors are starting to take notice of this company, which has undertaken numerous acquisitions and management additions in order to boost its standing in a booming industry.
As interest and volume have picked up since early in the year, there are numerous reasons to believe that such actions are justified. Premier has demonstrated the ability to land high-profile clients, which include big players such as Exxon (XOM), Coca-Cola (KO), and Bank of America (BAC), and land big contracts, as demonstrated by the deal with the Department of Defense (DOD) to conduct energy audits of two large bases in California.
Premier has also boosted its revenue streams in other areas of its advisory and consulting services and has made huge strides within its GreenHouse division, which has thrust itself into the market of advising municipalities, businesses, corporations - and the DOD - on how to cut costs through means of energy efficiency.
The resume is there for this growing OTC company. The recent spurt of good news from the past few months has circulated to investors, who look to have digested the news as the basis for building a solid foundation in a potential growth story.
For full version visit: http://vfcsstockhouse.com/blog/article/-mid-week-stock-watch-hgsi-trov-onty-siri-pimo
For full report visit: http://vfcsstockhouse.com/blog/article/-immunocellular-therapeutics-imuc-any-pullback-may-mean-opportunity
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
